CHANG CHAWNSHANG has a total of 18 patent applications. Its first patent ever was published in 2001. It filed its patents most often in WIPO (World Intellectual Property Organization) and United States. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are AREXIS AB, UNIV JOHNS HOPKINS MED and ANTICANCER INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 10 | |
#2 | United States | 8 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Agriculture | |
#5 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Microorganisms | |
#5 | Animal care | |
#6 | Analysing materials | |
#7 | Measuring microorganism processes | |
#8 | Acyclic or carbocyclic compounds | |
#9 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Chang Chawnshang | 18 |
#2 | Lee Kuo-Hsiung | 2 |
#3 | Itokawa Hideji | 2 |
#4 | Wang Hui-Kang | 2 |
#5 | Ishida Junko | 2 |
#6 | Shih Charles C-Y | 1 |
#7 | Lee Yi-Fen | 1 |
#8 | Ohtsu Hironori | 1 |
#9 | Yeh Shuyuan | 1 |
#10 | Ohtsu Hironari | 1 |
Publication | Filing date | Title |
---|---|---|
US2011028538A1 | Methods and compositions related to TR4 ligand | |
WO2010017257A2 | Psa and klk2 as therapeutic targets and molecules inhibiting psa and klk2 | |
WO2005062760A2 | Non-androgen dependent roles for androgen receptor and non-androgen related inhibitors of androgen receptor | |
US2006270643A1 | Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells | |
US2006270591A1 | Androgen receptor coregulators |